Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial [Yahoo! Finance]
Aclaris Therapeutics, Inc. (ACRS)
Last aclaris therapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
aclaristx.com
Company Research
Source: Yahoo! Finance
The open-label trial aims to assess the safety, tolerability, pharmacokinetics, and efficacy of ATI-2138 in AD patients over 12 weeks. Being conducted in the US, the trial plans to enrol approximately 15 subjects. Its primary endpoints focus on safety parameters while the secondary endpoints measure efficacy through Eczema Area and Severity Index (EASI) responses, including EASI-50; EASI-75; and EASI-90, as well as Validated Investigator Global Assessment (vIGA) responses; body surface area (BSA) responses; and other relevant measures. Topline data from this trial is anticipated in the first half of next year. ATI-2138 is an investigational oral covalent interleukin-2-inducible T-cell kinase (ITK) and Janus kinase (JAK) 3 inhibitor. The asset is being developed as a potential treatment for T-cell-mediated autoimmune diseases by disrupting T-cell signalling through the inhibition of ITK/JAK3 pathways in lymphocytes. Aclaris Therapeutics is dedicated to creating new treatme
Show less
Read more
Impact Snapshot
Event Time:
ACRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACRS alerts
High impacting Aclaris Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ACRS
News
- Aclaris Therapeutics And 2 Other US Penny Stocks To Watch [Yahoo! Finance]Yahoo! Finance
- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating.MarketBeat
- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.MarketBeat
- Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments [Yahoo! Finance]Yahoo! Finance
- ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs [Yahoo! Finance]Yahoo! Finance
ACRS
Earnings
- 11/6/24 - Miss
ACRS
Sec Filings
- 11/21/24 - Form SC
- 11/20/24 - Form 4
- 11/18/24 - Form 3
- ACRS's page on the SEC website